This slide show highlights some of the top breast cancer news of 2016, including a study looking at optimal margins in DCIS, a trial on biosimilars, a new FDA approval, and more.
Camizestrant Significantly Improves PFS in HER2– Breast Cancer
Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.
Applying Updated Breast Cancer Findings From ASCO to Clinical Practice
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Inavolisib-Based Therapy Boosts Progression-Free Survival in Breast Cancer
Inavolisib-based therapy reaches the primary end point of the phase 3 INAVO120 study among patients with PIK3CA-mutated breast cancer.
Finding a Place for Exercise Oncology in the Treatment of Breast Cancer
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
Bria-IMT Regimen Exceeds Survival Data of SOC in Metastatic Breast Cancer
Four of 13 patients with metastatic breast cancer recruited in 2022 for the phase 2 clinical study evaluating Bria-IMT remain in survival follow-up.
Breast Cancer Breakthroughs: 2024 ESMO Highlights
Neil M. Iyengar, MD, highlighted the most important data in breast cancer to come from 2024 ESMO.